Jump to main content
Jump to site search


Targeted and NIR Light-Controlled Delivery of Nitric Oxide Combined with Platinum (IV) Prodrug for Enhanced Anticancer Therapy

Abstract

This study reports a strategy of combining a Pt(IV) prodrug and ruthenium nitrosyl (Ru-NO) donor into a single nanoplatform {N-GQDs@Ru-NO-Pt@FA}, 1, in which platinum(IV) prodrug, Ru-NO and a forlic acid directing molecule were covalently decorated on N-doped graphene quantum dots (N-GQDs) . After cellular uptake of nanoplatform 1, the platinum(IV) prodrug was reduced into active anti-cancer Pt(II) species inside the cancerous cells, from which NO release was trigered by 808-nm NIR light illumination. Meanwhile, a prominent photothermal effect was noted as well. Nanoplatform 1 is capable of targeted intracellular co-delivery of Pt(II) and NO under 808-nm NIR light irradiation and combined with photothermal therapy, thus exerting high cytotoxicity toward cancer cells. This would have new implications for targeted combined-chemotherapy and NO-mediated multimodal phototherapy.

Back to tab navigation

Supplementary files

Publication details

The article was received on 18 Oct 2018, accepted on 02 Jan 2019 and first published on 03 Jan 2019


Article type: Paper
DOI: 10.1039/C8TB02743A
Citation: J. Mater. Chem. B, 2019, Accepted Manuscript
  •   Request permissions

    Targeted and NIR Light-Controlled Delivery of Nitric Oxide Combined with Platinum (IV) Prodrug for Enhanced Anticancer Therapy

    S. Shi, Y. Li, Q. Zhang, S. Yang and J. Liu, J. Mater. Chem. B, 2019, Accepted Manuscript , DOI: 10.1039/C8TB02743A

Search articles by author

Spotlight

Advertisements